Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone

L de Haan; J Lavalaye; D Linszen; P M Dingemans; J Booij

doi:10.1176/appi.ajp.157.6.1019

Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone

Am J Psychiatry. 2000 Jun;157(6):1019-20. doi: 10.1176/appi.ajp.157.6.1019.

Authors

L de Haan¹, J Lavalaye, D Linszen, P M Dingemans, J Booij

Affiliation

¹ Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands. ldehaan@amc.uva.nl

PMID: 10831489
DOI: 10.1176/appi.ajp.157.6.1019

Abstract

Objective: The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia.

Method: Subjective experience, psychopathology, and extrapyramidal symptoms were assessed, and D(2) receptor occupancy was determined with [(123)I]iodobenzamide single photon emission computed tomography, in 22 patients whose schizophrenia was stabilized by olanzapine or risperidone.

Results: Subjective experience, depression, and negative symptoms were related to dopamine D(2) receptor occupancy, but extrapyramidal symptoms were not.

Conclusions: These results provide preliminary evidence that negative subjective experience is related to high D(2) receptor occupancy. Longitudinal study is required because this relationship may have implications for dosing strategies.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Antipsychotic Agents / adverse effects
Antipsychotic Agents / therapeutic use*
Basal Ganglia Diseases / chemically induced
Basal Ganglia Diseases / diagnosis
Benzamides
Benzodiazepines
Corpus Striatum / diagnostic imaging
Corpus Striatum / metabolism*
Female
Health Status
Humans
Iodine Radioisotopes
Male
Olanzapine
Pirenzepine / adverse effects
Pirenzepine / analogs & derivatives*
Pirenzepine / therapeutic use
Psychiatric Status Rating Scales / statistics & numerical data
Pyrrolidines
Receptors, Dopamine D2 / metabolism*
Risperidone / adverse effects
Risperidone / therapeutic use*
Schizophrenia / diagnosis
Schizophrenia / diagnostic imaging
Schizophrenia / drug therapy*
Schizophrenic Psychology*
Tomography, Emission-Computed, Single-Photon / statistics & numerical data

Substances

Antipsychotic Agents
Benzamides
Iodine Radioisotopes
Pyrrolidines
Receptors, Dopamine D2
Benzodiazepines
Pirenzepine
3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Risperidone
Olanzapine